W. Timothy Garvey, MD, University of Alabama at Birmingham, USA
In this ADA 2026 expert interview, MedJ speaks with Dr. W. Timothy Garvey about the evolving goals of obesity management in the era of modern pharmacotherapy. As a Master of the AACE and a leading authority in obesity, Dr. Garvey discusses how “obesity remission” may be defined, how clinicians should set long-term treatment goals, and how metabolic improvements should be assessed. He also shares his perspective as a key investigator in the OASIS-1 trial, including which patient subgroups showed noteworthy responses and what these findings may suggest about obesity heterogeneity and treatment selection. In addition, Dr. Garvey reflects on the integration of obesity management into diabetes care, with a focus on treatment duration, timing of dose optimization, and key assessment milestones in long-term follow-up after initiating novel anti-obesity pharmacotherapy.